[Value of potassium canrenoate in the prevention of arrhythmia during the acute phase of myocardial infarction].
This study was based on a series of 486 patients with acute myocardial infarction. All were treated with heparin and nitrite derivatives. 320 patients received 600 mg/24 h Potassium Canrenoate for 5 days (long duration); 90 patients received 1000 mg of Potassium for the first 36 hours only. 76 patients did not receive the drug and served as controls. The biochemical changes due to Potassium Canrenoate are discussed with special emphasis on the serum and intraerythrocytic potassium levels. The antiarrhythmic action of the potassium was assessed directly (the number of ventricular extra systoles decreased significantly) and indirectly (the amount of antiarrhythmic therapy required in association was three times less in patients treated by Potassium Canrenoate). The mortality rate changed from 17 to 12%. The beneficial effect of Potassium Canrenoate is attributed to the maintenance or the restoration normal potassium levels of ischaemic myocardial tissue.
D000208:Acute Disease; D000368:Aged; D001145:Arrhythmias, Cardiac / Q000209:etiology / Q000517:prevention & control*; D002191:Canrenoic Acid / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D004573:Electrolytes / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy*; D011245:Pregnadienes / Q000627:therapeutic use*; D014508:Urea / Q000097:blood
D004573:Electrolytes; D011245:Pregnadienes; D002191:Canrenoic Acid; D014508:Urea; D003404:Creatinine
Intérêt du canrénoate de potassium dans la prévention des troubles du rythme à la phase aiguë de l'infarctus du myocarde.